Literature DB >> 7542253

Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.

J W Xuan1, C Hota, Y Shigeyama, J A D'Errico, M J Somerman, A F Chambers.   

Abstract

Osteopontin (OPN) is a secreted calcium-binding phosphoprotein produced in a variety of normal and pathological contexts, including tissue mineralization and cancer. OPN contains a conserved RGD (arg-gly-asp) amino acid sequence that has been implicated in binding of OPN to cell surface integrins. To determine whether the RGD sequence in OPN is required for adhesive and chemotactic functions, we have introduced two site-directed mutations in the RGD site of the mouse OPN cDNA, in which the RGD sequence was either deleted or mutated to RGE (arg-gly-glu). In order to test the effect of these mutations on OPN function, we expressed control and mutated mouse OPN in E. coli as recombinant glutathione-S-transferase (GST)-OPN fusion proteins. Control mouse GST-OPN was functional in cell adhesion assays, supporting attachment and spreading of mouse (malignant PAP2 ras-transformed NIH 3T3, and, to a lesser extent, normal NIH 3T3 fibroblasts) and human (MDA-MB-435 breast cancer, and normal gingival fibroblast) cells. In contrast, neither of the RGD-mutated OPN proteins ("delRGD" or "RGE") supported adhesion of any of the cell lines, even when used at high concentrations or for long assay times. GRGDS (gly-arg-gly-asp-ser) peptides inhibited cell adhesion to intact GST-OPN, as well as to fibronectin and vitronectin. In chemotaxis assays, GST-OPN promoted directed cell migration of both malignant (PAP2, MDA-MB-435) and normal (gingival fibroblast, and NIH 3T3) cells, while RGD-mutated OPN proteins did not. Together these results suggest that the conserved RGD sequence in OPN is required for the majority of the protein's cell attachment and migration-stimulating functions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542253     DOI: 10.1002/jcb.240570413

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  18 in total

1.  Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer.

Authors:  Alison L Allan; Rosamma George; Sharon A Vantyghem; Mark W Lee; Nicole C Hodgson; C Jay Engel; Ron L Holliday; David P Girvan; Leslie A Scott; Carl O Postenka; Waleed Al-Katib; Larry W Stitt; Toshimitsu Uede; Ann F Chambers; Alan B Tuck
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 2.  Delayed expression of osteopontin after focal stroke in the rat.

Authors:  X Wang; C Louden; T L Yue; J A Ellison; F C Barone; H A Solleveld; G Z Feuerstein
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

Review 3.  Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation.

Authors:  A O'Regan; J S Berman
Journal:  Int J Exp Pathol       Date:  2000-12       Impact factor: 1.925

Review 4.  Osteopontin: an effector and an effect of tumor metastasis.

Authors:  L A Shevde; S Das; D W Clark; R S Samant
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

5.  Role of plasma osteopontin as a biomarker in locally advanced breast cancer.

Authors:  Pieter H Anborgh; Laura Br Caria; Ann F Chambers; Alan B Tuck; Larry W Stitt; Muriel Brackstone
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

6.  Overlapping functions of bone sialoprotein and pyrophosphate regulators in directing cementogenesis.

Authors:  M Ao; M B Chavez; E Y Chu; K C Hemstreet; Y Yin; M C Yadav; J L Millán; L W Fisher; H A Goldberg; M J Somerman; B L Foster
Journal:  Bone       Date:  2017-09-01       Impact factor: 4.398

Review 7.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

8.  Osteopontin splice variant as a potential marker for metastatic disease in pancreatic adenocarcinoma.

Authors:  Ali A Siddiqui; Elizabeth Jones; Darren Andrade; Apeksha Shah; Thomas E Kowalski; David E Loren; Galina Chipitsyna; Hwyda A Arafat
Journal:  J Gastroenterol Hepatol       Date:  2014-06       Impact factor: 4.029

9.  Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata.

Authors:  M Zöller; P Freyschmidt-Paul; M Vitacolonna; K J McElwee; S Hummel; R Hoffmann
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

10.  RANKL, osteopontin, and osteoclast homeostasis in a hyperocclusion mouse model.

Authors:  Cameron G Walker; Yoshihiro Ito; Smit Dangaria; Xianghong Luan; Thomas G H Diekwisch
Journal:  Eur J Oral Sci       Date:  2008-08       Impact factor: 2.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.